Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. [electronic resource]
Producer: 20051108Description: 6615-24 p. digitalISSN:- 1078-0432
- AC133 Antigen
- Acute Disease
- Adult
- Aged
- Antigens, CD -- analysis
- Antineoplastic Agents -- adverse effects
- CD146 Antigen
- Constipation -- chemically induced
- Diarrhea -- chemically induced
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Endothelial Cells -- chemistry
- Female
- Glycoproteins -- analysis
- Hematologic Neoplasms -- blood
- Humans
- Leukemia -- blood
- Leukocyte Common Antigens -- analysis
- Male
- Microtubules -- metabolism
- Middle Aged
- Mutation
- Myelodysplastic Syndromes -- blood
- Nausea -- chemically induced
- Neoplasm Recurrence, Local
- Neoplastic Cells, Circulating -- chemistry
- Neural Cell Adhesion Molecules -- analysis
- Peptides -- analysis
- Platelet Endothelial Cell Adhesion Molecule-1 -- analysis
- Sulfonamides -- adverse effects
- Treatment Outcome
- Tubulin -- genetics
- Vomiting -- chemically induced
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.